Centre for Eye Research Australia
Australia’s first clinical trials of an investigational gene therapy to treat dry age-related macular degeneration (AMD) have begun at the Centre for Eye Research Australia (CERA).
CERA’s Principal Investigator of Retinal Gene Therapy Research and vitreoretinal surgeon Dr Tom Edwards performed the first surgeries to administer the investigational gene therapy to patients at the Royal Victorian Eye and Ear Hospital in Melbourne.
This investigational gene therapy, being developed by Gyroscope Therapeutics Limited, is being studied in two studies evaluating its safety and effectiveness for the treatment of geographic atrophy (GA) secondary to AMD.
However, lack of awareness among people about eye disorders, poor primary healthcare infrastructure, and lack of insurance in developing countries hamper growth of the global ophthalmic devices market. In addition, eye diseases in children are also increasing due to the general lack of awareness.
The global ophthalmic devices market is anticipated to grow from an estimated USD 29,171.5 million in 2014 to
USD 42,685.1 million in 2020 at a
CAGR of 6.5% during the forecast period.
Age-related eye diseases, such as glaucoma, cataract, diabetic retinopathy, and age-related macular degeneration, are the leading causes of visual impairment and blindness in North America. According to the American Academy of Ophthalmology, approximately 22 million Americans aged 40 and above were affected by cataract and 2.3 million Americans were affected by glaucoma in 2011.
Review of Myopia Management and Plano Announce New Content Partnership
USA - English
Share this article
(RMM) is pleased to announce a new partnership with the Singapore-based Healthtech company, Plano Pte Ltd. Under their new agreement,
RMM and Plano will produce new educational content designed specifically for eye care professionals worldwide. By joining forces, the companies hope to expand their current platforms and engage with the growing international myopia management community.
Jobson Optical Group launched
RMM in March 2019 to create and share the most up-to-date information and educational tools for eye care providers (ECPs). Over the last two years,
RMM has established itself as the first multi-platform digital asset dedicated entirely to myopia management.
Review of Myopia Management and Plano Announce New Content Partnership prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Gene Therapy Shows Potential for Repairing Damage Caused by Glaucoma and Dementia
Source: Science photo library-ktsdesign/Getty Images
April 1, 2021
Share
Research by scientists at the University of Cambridge has demonstrated how gene therapy might help to repair some of the damage caused by chronic neurodegenerative conditions such as glaucoma and dementia. Their studies in rodents demonstrated how delivering two genes simultaneously using a single vector stimulated axonal transport in a humanized tauopathy model of Alzheimer’s disease, and in an experimental glaucoma model. Encouragingly, the results, reported in
Science Advances, showed “promising evidence” that the gene therapy might result in improvement in short-term memory in the tauopathy model of dementia. The team said the studies also highlight the potential effectiveness of gene therapy for treating complex polygenic conditions that have no single genetic cause.